Source comparison
PT-141 Clinical Trials 2026 Comparison: Trial Design, Populations, and Primary Endpoints
The table below summarizes the key PT-141 clinical trials 2026 currently active or recently completed, comparing study populations, dosing regimens, and primary endpoints across Phase II and Phase III protocols. Phase III Premenopausal women with HSDD 1.75mg S
This comparison does not assign a generated winner or score.
- The table below summarizes the key PT-141 clinical trials 2026 currently active or recently completed, comparing study populations, dosing regimens, and primary endpoints across Phase II and Phase III protocols.
- Phase III
- Premenopausal women with HSDD
- 1.75mg SC, on-demand
- Increase in satisfying sexual events + reduction in distress
- +2.1 events/month vs +0.7 placebo
- Nausea 40%, flushing 28%, transient hypertension 12%
- Enrolling through Q3 2026
- Phase II
- Males with psychogenic ED
- Subjective arousal score (IIEF desire domain)
- 58% response vs 22% placebo
- Nausea 38%, headache 15%, flushing 25%
- Completed, data published Q4 2025
- Post-SSRI sexual dysfunction (women)
- Restoration of orgasmic function (FSFI orgasm subscale)
- 54% vs 18% placebo
- Nausea 42%, dizziness 10%
- Active, interim analysis pending
- Premenopausal women with HSDD (long-term safety)
- 1.75mg SC, on-demand for 52 weeks
- Adverse event incidence, cardiovascular safety
- N/A (safety study)
- No serious AEs; nausea tachyphylaxis observed
- Ongoing
- This table demonstrates the consistency of PT-141 clinical trials 2026 dosing—1.75mg subcutaneous remains the standard across all populations—and the convergence on patient-reported satisfaction and distress as co-primary endpoints. The nausea incidence is remarkably stable across trials, suggesting it's a true pharmacological effect rather than cohort-specific. Importantly, no PT-141 clinical trials 2026 have reported serious cardiovascular adverse events when strict inclusion criteria are enforced.